In recent months the novel coronavirus, 2019-nCoV (COVID-19 and SARS-CoV-2), has quickly risen to a global health concern. Originating from Wuhan, China, the number of coronavirus cases reported outside of mainland China continues to increase. As of late March 17, 2020, the outbreak has resulted in over 194,000 illnesses and over 7800 deaths around the globe, according to the World Health Organization (WHO).
To combat the spread of this infectious disease, researchers and healthcare workers around the world are working tirelessly to make new discoveries about the virus with the ultimate goal of developing a vaccine. Cedarlane is proud to offer products and resources from some of the world’s top life science brands to assist in this research. Please find more information included below.
Cedarlane Updates: Cedarlane is monitoring and responding to the COVID-19 pandemic as the situation develops, both nationally and internationally. We have enacted numerous on-site policies at both of our offices in Canada and in the United States to protect our employees and our local communities, while continuing to provide the products that our customers require. Click here for more information.
COVID-19: Biomarkers to Distinguish Severity and Prognosis
Presented by HyTest
DATE/TIME: Thu, May 7, 2020 11:00 AM - 12:00 PM EST
Detecting and measuring the levels of SARS-CoV-2 antibodies as a result of exposure to COVID-19 will provide valuable information on the development of individual immunity. In addition, screening and monitoring for the various health issues that may arise as part of COVID-19 disease management are also needed. During the webinar, the importance of serological testing of SARS-CoV-19, as well as major predictors of COVID-19 severity, will be described. Included in this webinar:
- the use of nucleic acid testing and serological testing for diagnostics of COVID-19, as well as the benefits and limitations of these methods for COVID-19 diagnostics
- the effects of SARS-CoV-2 on the cardiovascular system
- the role of cardiac and inflammatory biomarkers in distinguishing the severity and prognosis of COVID-19
Rockland's Effort in the Fight Against the Global Pandemic
Presented by Rockland
DATE/TIME: Thu, May 7, 2020 2:00 PM BST | 9:00 AM EST
Coronaviruses (CoV) are a family of viruses that range from the common cold to more severe diseases such as Middle East Respiratory Syndrome (MERS-CoV) and Severe Acute Respiratory Syndrome (SARS-CoV). The current outbreak is attributed to a novel coronavirus (COVID-19), which is a new strain not previously identified in humans and believed to have originated in bats. However, human-to-human transfer is occuring via droplet inspiration, as is the case with most respiratory viruses.
The outbreak of COVID-19 was declared a public health emergency of international concern by the WHO, pressuring researchers worldwide to develop a treatment. As a trusted provider to the research community, Rockland has products and services that support the study of COVID-19 including specific antibodies capable of detecting the 2019-nCov. Included in this webinar:
- How Rockland has been combatting COVID-19
- Key products and services that are or can be used in current COVID-19 research
- New products in the pipeline that will support the ongoing efforts in ending the pandemic
Vaccine Development for COVID-19
Presented by Sino Biological
DATE/TIME: Thu, May 21, 2020 | 2:30 PM - 3:30 PM EST
COVID-19 has become a major global health threat, approaching 2 million cases globally, and now extending into developing nations of Africa, Asia, and Latin America. Low-cost affordable vaccines to prevent COVID-19 are under development at the Texas Children's Center for Vaccine Development of the National School of Tropical at Baylor College of Medicine. Our technology is a recombinant protein vaccine similar to the one used to prevent hepatitis B. One vaccine is advancing into clinical testing, while a second will follow in 2021.
The COVID-19 pandemic is caused by a newly discovered coronavirus, SARS-Cov-2. To characterize and detect this new virus, antibodies to support scientific research, diagnosis and vaccine development are in urgent need. Sino Biological, Inc. develops specific S and N antibodies to SARS-Cov-2 by several antibody generation platforms, including hybridoma, B cell antibody cloning and antibody phage display library. Meanwhile, we also obtained antibodies to recognize all 7 strains of coronaviruses that infected humans. Several candidates are selected for further analysis in research, potential diagnosis applications, and to facilitate vaccine development.
Multiplex Serological Assays for COVID-19
Presented by Sino Biological
DATE/TIME: Wed, May 27, 2020 | 1:00 PM - 2:00 PM EST
Vitalant Research Institute (VRI) has developed and is driving two large studies related to SARS-CoV-2/COVID-19. One study, funded by the NHLBI and NIAID, is titled RESPONSE (REDS Epidemiology, Surveillance and Preparedness of the Novel SARS-CoV-2 Epidemic). The RESPONSE study will evaluate the rates of SARS-CoV-2 RNA in 300,000 donations in minipools and SARS-CoV-2 Abs 36,000 donations in 6 US blood collection regions. It will also track rates of COVID-19 post-donation information (PDI) reports with donation plasma tested for RNA, recipients tested to investigate potential transfusion transmission, as well as 150 PDI donors with infection followed for 12 months with collection of longitudinal serum and PMBC samples for characterization of immune responses over time and to establish a sharable repository for pathogenesis and vaccine research.
In addition, we are leading a large CDC-funded national serosurvey to apply SARS-CoV-2 Ab assays to test 340,000 blood donor samples collected in monthly serial cross-sectional waves in 25 regions within the US. This study will also follow 150 convalescent plasma donors for 18 months with characterization of SARS-CoV-2 antibody dynamics over time using multiple high-throughput platforms, a novel pseudotyped SARS-CoV-2 reporter viral particle neutralizing assay to perform high-throughput titration to qualify COVID-19 Convalescent Plasma (CCP), and a respiratory viral protein array assay developed by Dr. Philip Felgner’s team at UC Irvine in partnership with Sino Biological.